key: cord-0762911-5bmcjhut authors: Rose, Liam; Graham, Laura; Koenecke, Allison; Powell, Michael; Xiong, Ruoxuan; Shen, Zhu; Kinzler, Kenneth W.; Bettegowda, Chetan; Vogelstein, Bert; Konig, Maximilian F.; Athey, Susan; Vogelstein, Joshua T.; Wagner, Todd H. title: The Association Between Alpha-1 Adrenergic Receptor Antagonists and In-Hospital Mortality from COVID-19 date: 2020-12-22 journal: medRxiv DOI: 10.1101/2020.12.18.20248346 sha: e0c463f4bbdd9cf444f28dcec2a476d6afea5ed1 doc_id: 762911 cord_uid: 5bmcjhut Effective therapies for coronavirus disease 2019 (COVID-19) are urgently needed, and preclinical data suggest alpha-1 adrenergic receptor antagonists (α(1)-AR antagonists) may be effective in reducing mortality related to hyperinflammation. Using a retrospective cohort design with patients in the Department of Veterans Affairs healthcare system, we use doubly robust regression and matching to estimate the association between use of α(1)-AR antagonists at time of hospitalization and likelihood of death due to COVID-19 during an inpatient stay. Having an active prescription for an α(1)-AR antagonist (tamsulosin, silodosin, prazosin, terazosin, doxazosin, or alfuzosin) at the time of admission had a significant negative association with in-hospital mortality (relative risk reduction 14%; odds ratio 0.75; 95% CI 0.66 to 0.86; p ≤ 0.001). These effects were also found in an expanded cohort of suspected COVID-19 patients, supporting the need for clinical trials. The viral replication phase in coronavirus disease 2019 (COVID-19) can be followed by a hyperinflammatory host immune response referred to as cytokine storm syndrome. This can lead to acute respiratory distress syndrome, multi-organ failure, and death despite maximal supportive care (1, 2) . Catecholamines amplify hyperinflammation by increasing cytokine production in immune cells (3) . Alpha-1 adrenergic receptor antagonists (⍺1-AR antagonists) can prevent cytokine storm syndrome and death in mice by blocking catecholamine signaling (4) . In a retrospective analysis of hospitalized patients presenting with acute respiratory distress or pneumonia, patients incidentally taking ⍺1-AR antagonists had a 34% relative risk reduction for being mechanically ventilated and dying compared to non-users (5) . The objective of this study was to examine the association of ⍺1-AR antagonist use with inhospital mortality in patients with COVID-19. We analyzed patients hospitalized at Veterans Health Administration (VA) hospitals, where ⍺1-AR antagonists are commonly used to treat benign prostatic hyperplasia (BPH), post-traumatic stress disorder (PTSD), and hypertension. We hypothesized that patients with COVID-19 taking ⍺1-AR antagonists at the time of hospital admission would be less likely to die during their hospitalization. We included all patients admitted to a VA hospital between February 20, 2020, and August 5, 2020 with a confirmed COVID-19 diagnosis ( Figure 1 ). Diagnosis codes for COVID-19 were identified from the Centers for Disease Control and Prevention (CDC) coding guidelines for COVID-19 (6, 7) . The VA COVID-19 Shared Data Resource was used to identify VA patients with a SARS-CoV-2 laboratory test result (8). This data resource combines VA-specific lab results with non-VA lab results using text extraction from patient medical records. Because over 90% of ⍺1-AR antagonist users in the analysis were older men, we excluded women to reduce unmeasured confounding in risk of respiratory conditions unrelated to COVID-19. We also excluded patients under age 45 and patients over age 85 given the strong relationship between the severity of COVID-19 and age. An expanded sample included all patients with laboratory-confirmed, "suspected positive", or "possible positive" COVID-19 according to National COVID Cohort Collaborative (N3C) criteria (9). This Suspected COVID-19 sample excluded patients who tested negative for COVID-19. This cohort was not operationally different from the main cohort on vital signs at admission (Supplementary Figure 1) . The primary outcome was death during the index hospitalization. The primary exposure variable was the use of ⍺1-AR antagonists at the time of admission for the index hospitalization. Active prescriptions of ⍺1-AR antagonists (tamsulosin, silodosin, prazosin, terazosin, doxazosin, or alfuzosin) were identified and defined by the patient having medication on hand on the day of the index admission, regardless of dosage. Secondary analyses examined the effect of tamsulosin (the most commonly prescribed ⍺1-AR antagonist) and doxazosin (a nonselective ⍺1-AR antagonist) alone. Finally, with in-hospital therapies in-flux during the early stage of the pandemic, we repeated the analysis by week and VA hospital to ensure results were not driven by any particular time or location. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The Association Between Alpha-1 Adrenergic Receptor Antagonists and In-Hospital Mortality from COVID-19 3 We obtained data on patient demographics, vital signs, and prescriptions from VA's corporate data warehouse (CDW). Patient comorbidities were based on the International Classification of Diseases, Version 10 codes from VA care in the prior year. Other physiologic variables, including oxygen saturation and temperature, were defined at time of inpatient admission. Analyses followed the methodology of a companion paper examining patients with acute respiratory distress and pneumonia (5) . Unadjusted analysis compared patients with ⍺1-AR antagonist prescriptions to all other patients with COVID-19 using Fisher's exact test. We then estimated propensity scores and trimmed the sample to ensure overlap in the propensity score distributions of the exposed and unexposed groups. On this reduced sample, the adjusted analysis used inverse propensity-weighted logistic regression adjusting for the patient age at admission (input as a demeaned cubic polynomial to allow a nonlinear relationship), calendar week, location of hospitalization, and comorbidities diagnosed any time in the two years prior to the index inpatient stay. This approach is "doubly robust" in that it uses the observed confounders in both the calculation of the propensity score and the odds ratios. Comorbidities included in the matching procedure were diabetes, hypertension, heart failure, ischemic heart disease, acute myocardial infarction, COPD, and PTSD. All of the control variables reflect information on the Veterans prior to admission with COVID-19. As noted above, we controlled for secular changes in COVID-19 care using calendar week, starting with February 20, 2020. We chose not to examine endpoints during the hospital stay, such as use of a ventilator or admission to the ICU, given this is based on physician coding or data structures that we cannot assure were handled uniformly, especially during surges. We also chose not to control for processes of care during the stay given this could introduce bias in the analysis. We then conducted a 5:1 matched analysis using the same covariates as the adjusted model (10). This approach assigns each exposed patient to a set of five unexposed patients most similar on observed characteristics and does not make assumptions about the functional form of the potential relationship between confounders and the outcome. Matches were selected using a greedy, nearestneighbor approach based on Mahalanobis distance (11). The matched analysis used the Cochran-Mantel-Haenszel test to obtain odds ratios, confidence intervals, and p-values. We also present relative risk reductions (RRR) for the matched cohorts, and the pre-and post-matching balance of covariates is shown in Figure 3 . The sample contained 12,266 patients with COVID-19, with 2,555 taking any ⍺1-AR antagonist at admission. Of those taking ⍺1-AR antagonists, 72% were on tamsulosin, and 4% were on doxazosin ( Figure 1 ). Table 1 provides sample characteristics. For patients admitted to a VA hospital between February 20, 2020, and August 5, 2020, the overall in-hospital mortality rate was 9%. Among patients with confirmed COVID-19 (5.5% of all admissions), in-hospital mortality was 17.3%. Patients with COVID-19 taking any ⍺1-AR antagonist, compared to non-users, had a 14% relative risk reduction for death (340/2,417 in matched treatment group vs. 1,383/8,422 in matched control group, p ≤ 0.001). . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted December 22, 2020. ; https://doi.org/10.1101/2020.12.18.20248346 doi: medRxiv preprint The Association Between Alpha-1 Adrenergic Receptor Antagonists and In-Hospital Mortality from COVID-19 4 The top panel in figure 2 shows the unadjusted, propensity score adjusted, and matched odds ratios among patients diagnosed with COVID-19 (n = 12,266). The bottom panel expands the denominator to include suspected positive cases (n = 16,866). The dark green odds ratios in Figure 2 represent all ⍺1-AR antagonists, while the lighter green represent doxazosin. Figure 2 shows that the results are similar for the Suspected COVID-19 sample. Patients taking ⍺1-AR antagonists, compared to non-users, had an 11% relative risk reduction for death (p ≤ 0.001) in this cohort ( Figure 2) . Use of doxazosin, a nonselective ⍺1-AR antagonist similar to prazosin used in preclinical studies of cytokine storm syndrome, resulted in a 43% relative risk reduction for death (11/101 in matched treatment group vs. 96/505 in matched control group, p=0.02, Figure 2 ). Use of tamsulosin, the most common ⍺1-AR antagonist in this cohort, had a 10% relative risk reduction for death (p = 0.01, Supplementary Figure 2 ). Even though COVID-19 has affected different parts of the US at different times, we found no evidence that these results were driven by any particular time period or location ( Supplementary Figures 3 and 4) . In this retrospective analysis of patients with confirmed and suspected COVID-19, we found a significant negative association between the use of ⍺1-AR antagonists and in-hospital mortality. Immune cells can express all ⍺1-AR subtypes (⍺1A-, ⍺1D-, and ⍺1B-AR), and catecholamine signaling through individual receptors may be highly redundant (1, 2) . Emerging preclinical data suggests that ⍺1-AR antagonists with nonselective effects on ⍺1A-, ⍺1D-, and ⍺1B-AR may be potent in mitigating hyperinflammation and preventing death in animal models of cytokine storm syndrome (3). In patients with suspected COVID-19, use of doxazosin, an antagonist on all three ⍺1-ARs, was associated with significantly reduced in-hospital mortality compared to controls (odds ratio for death 0.38 in adjusted and 0.51 in matched cohorts). A similar trend was seen in patients with confirmed COVID-19, but the sample size limited precision. Tamsulosin, by comparison, is a "uroselective" ⍺1-AR antagonist with antagonism on both ⍺1Aand ⍺1D-ARs expressed in prostatic tissue, without clinically relevant inhibition of ⍺1B-ARs expressed by immune cells and peripheral vasculature. Baseline tamsulosin use in patients with confirmed and suspected COVID-19 was associated with significant, but less pronounced reductions in in-hospital mortality (Supplementary Figure 2) , consistent with a potential redundancy in catecholamine signaling through the ⍺1B-AR (12). One concern with observational analysis is confounding by indication, especially if medication use is correlated with disease severity. This analysis examines Veterans' use of ⍺1-AR antagonists prior to hospitalization. These medications are often used to manage chronic conditions, and prescribing practices would not be biased by the severity of COVID-19. In addition, the results were not driven by a specific location or time period. This study has some important strengths and weaknesses. A strength is the focus on mortality thereby avoiding process measures, such as use of ventilators or admission to an ICU, that could be biased if clinicians or hospitals changed their practices in unobserved ways. Another strength is our use of information prior to the COVID-19 admission for risk adjustment. We also did not control for process of care during the stay, which might induce biases. One limitation in this study was the exclusion of women because ⍺1-AR antagonists are most commonly used to treat benign prostatic hyperplasia, and 90% of patients in the VA system are men (13). A second limitation was our inability to examine dose effects given our sample size. These issues would need to be evaluated in a prospective clinical trial. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted December 22, 2020. ; https://doi.org/10.1101/2020.12.18.20248346 doi: medRxiv preprint The Association Between Alpha-1 Adrenergic Receptor Antagonists and In-Hospital Mortality from COVID-19 5 The results highlight the need for prospective, controlled clinical trials to examine the efficacy of doxazosin for reducing in-hospital mortality and other adverse outcomes from COVID-19. ⍺1-AR antagonists are inexpensive, administered orally, and have an established safety profile. Thus, if trials confirm these results, ⍺1-AR antagonists could be widely deployed. Prior research has shown that ⍺1-AR antagonists were associated with fewer adverse outcomes for patients with pneumonia (5), so a clinical trial might reveal options for mitigating the cytokine storm resulting from pneumonia, COVID-19, or another coronavirus. In summary, this study suggests that male patients with laboratory-confirmed, "suspected positive", or "possible positive" COVID-19 diagnosis had lower odds of mortality if they had an active prescription for an ⍺1-AR antagonist (tamsulosin, silodosin, prazosin, terazosin, doxazosin, or alfuzosin) at the time of admission (relative risk reduction 14%). There was considerable variation by type of ⍺1-AR antagonist. Doxazosin was associated with 43% relative risk reduction for death, while tamsulosin, the most common ⍺1-AR antagonist in this cohort, had a 10% relative risk reduction for death. A clinical trial testing the efficacy of an ⍺1-AR antagonist, most likely doxazosin, would appear warranted. In 2017, The Johns Hopkins University (JHU) filed a patent application on the use of various drugs to prevent cytokine release syndromes, on which VS, RB, NP, BV, KWK, and SZ are listed as inventors. JHU will not assert patent rights from this filing for treatment related to COVID-19. MFK received personal fees from Bristol-Myers Squibb and Celltrion. BV, KWK, and NP are founders of and hold equity in Thrive Earlier Detection. KWK and NP are consultants to and are on the Board of Directors of Thrive Earlier Detection. BV, KWK, NP, and SZ are founders of, hold equity in, and serve as consultants to Personal Genome Diagnostics. SZ holds equity in Thrive Earlier Detection and has a research agreement with BioMed Valley Discoveries, Inc. KWK and BV are consultants to Sysmex, Eisai, and CAGE Pharma and hold equity in CAGE Pharma. NP is an advisor to and holds equity in Cage Pharma. BV is also a consultant to Nexus. KWK, BV, SZ, and NP are consultants to and hold equity in NeoPhore. CB is a consultant to Depuy-Synthes and Bionaut Pharmaceuticals. CB, BV, KWK, and NP are also inventors on technologies unrelated or indirectly related to the work described in this article. Licenses to these technologies are or will be associated with equity or royalty payments to the inventors, as well as to JHU. The terms of all these arrangements are being managed by JHU in accordance with its conflict of interest policies. SA is an advisor and holds an equity stake in two private companies, Prealize (Palo Alto, California, USA) and Dr. Consulta (Brazil). Prealize is a health care analytics company, and Dr. Consulta operates a chain of low-cost medical clinics in Brazil. JV, BV, CB, and MK conceived of the precented idea. LR, LG, AK, MP, and RX conducted statistical analyses and results presentation. AK, MP, RX, ZS, and SA developed the methodology. LR, JV, TW wrote the manuscript with input from all authors. All authors reviewed the final manuscript. The work of Allison Koenecke is supported by the National Science Foundation Graduate Research Fellowship under Grant No. DGE -1656518. Dr. Konig was supported by the National . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. ) 8900 (72.6%) Note: CAD = coronary artery disease, CHF = congestive heart failure, COPD = chronic obstructive pulmonary disease, MI = acute myocardial infarction, BPH = benign prostatic hyperplasia, PTSD = post-traumatic stress disorder. PTSD was excluded from the adjusted analysis due to collinearity with other comorbidities. Listed VA hospitals had the most COVID-19 inpatient hospitalizations during the study period. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Figure 3 . Standardized mean differences in patient characteristics before and after matching for both the diagnosed (A) and suspected (B) cohorts . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) preprint The copyright holder for this this version posted December 22, 2020. ; https://doi.org/10.1101/2020.12.18.20248346 doi: medRxiv preprint HLH Across Speciality Collaboration, UK. COVID-19: consider cytokine storm syndromes and immunosuppression Preventing cytokine storm syndrome in COVID-19 using α-1 adrenergic receptor antagonists Functional α1-adrenergic receptors on leukocytes of patients with polyarticular juvenile rheumatoid arthritis Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome Alpha-1 adrenergic receptor antagonists to prevent acute respiratory distress syndrome and death from cytokine storm syndrome ICD-10-CM official coding guidance interim advice for cornavirus CDC. ICD-10-CM official coding and reporting guidleines COVID-19 Guidelines Any opinion, findings, and conclusions or recommendations expressed in this material are those of the authors and do not necessarily reflect the views of the US Department of Veterans Affairs or the National Science Foundation. This project was sponsored by the VA Office of Reporting, Analytics, Performance, Improvement and Deployment, and the VA Center for Medication Safety, and approved as quality improvement by the Stanford University Institutional Review Board.